SKAN Group AG (SWX:SKAN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 1.04B -28.0% |
| Revenue (ttm) | 333.34M -7.7% |
| Net Income | 16.27M -58.1% |
| EPS | 0.72 -58.1% |
| Shares Out | 22.48M |
| PE Ratio | 64.04 |
| Forward PE | 34.20 |
| Dividend | 0.22 (0.47%) |
| Ex-Dividend Date | May 11, 2026 |
| Volume | 8,442 |
| Average Volume | 26,371 |
| Open | 47.45 |
| Previous Close | 46.65 |
| Day's Range | 46.35 - 47.45 |
| 52-Week Range | 35.75 - 77.80 |
| Beta | 0.71 |
| RSI | 50.27 |
| Earnings Date | Aug 18, 2026 |
About SKAN Group AG
SKAN Group AG, together with its subsidiaries, provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally. It operates in two segments, Equipment and Solutions; and Services and Consumables. The company offers accessories, biological indicators, digital ventures, isolators, cleanroom, laminar flow, particle counter, personal protective equipment, safety workbench, transfer systems, and fume cupboard. It also provides digital solutions, lifecy... [Read more]
Financial Performance
In 2025, SKAN Group AG's revenue was 333.34 million, a decrease of -7.74% compared to the previous year's 361.30 million. Earnings were 16.27 million, a decrease of -58.06%.
Financial StatementsNews
SKAN Group AG Earnings Call Transcript: H2 2025
Order intake grew 3.1% to CHF 370.6 million, but net sales fell 7.7% due to project delays, with profitability rebounding in H2. Strategic acquisitions and robust Services and Consumables growth support a positive outlook, with 2026 sales expected to rise in the upper teens percentage range.
SKAN Group AG Earnings Call Transcript: H1 2025
Order intake rose 20% year-over-year, but net sales fell 17.8% due to project delays, impacting EBITDA. Record backlog and strong cash flow support a positive outlook, with guidance reaffirmed for mid-teens sales growth and 14%-16% EBITDA margin.
SKAN Group AG Transcript: CMD 2025
Digital integration and pre-approved services are central to future growth, with a focus on ramping up new facilities and leveraging first-mover advantages. Market demand is driven by ADCs and GLP-1s, while organizational strengths and a stable regulatory environment support long-term strategy.
SKAN Group AG Earnings Call Transcript: H2 2024
Order intake surged 21.8% year-over-year, with net sales up 13% to CHF 361 million and EBITDA margin at 15.8%. Strong order backlog and investments support a positive outlook, though project delays shift some growth into 2025. Dividend rises 14% to CHF 0.40 per share.
SKAN Group AG Earnings Call Transcript: H1 2024
Order intake and net sales grew solidly, with EBITDA and margins in line with guidance. Strong order backlog and pipeline support a positive outlook, with investments in Pre-Approved Services and Aseptic Technologies driving future growth.